The findings presented here highlight recently identified roles for PADs in GBM, the need to assess PAD isozyme-specific processes in the heterogeneity of GBM and the potential for tailored treatment of GBM subtypes, using targeted PAD isozyme-specific inhibitors. Here, PADI4 is linked to glioblastoma.